Published in N Engl J Med on November 23, 2000
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer | NCT02343614
Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction | NCT00026819
The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26
Shared health governance. Am J Bioeth (2011) 6.94
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. N Engl J Med (2005) 4.48
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med (2012) 3.51
Prostaglandins and cancer. Gut (2005) 3.44
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Classical peer review: an empty gun. Breast Cancer Res (2010) 2.97
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med (2009) 2.80
Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials (2009) 2.77
EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 2.75
Conflicts of interest: how money clouds objectivity. J R Soc Med (2006) 2.71
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
The double-edged sword of COX-2 selective NSAIDs. CMAJ (2002) 2.57
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS One (2007) 2.52
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials (2006) 2.50
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Reporting bias in medical research - a narrative review. Trials (2010) 2.44
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol (2004) 2.32
Lapses at the new England journal of medicine. J R Soc Med (2006) 2.22
Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf (2013) 2.15
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ (2005) 2.03
Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ (2007) 2.02
Balancing benefits and harms in health care. BMJ (2003) 2.01
A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med (2009) 1.99
The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest (2002) 1.98
Outcome of non-invasive treatment modalities on back pain: an evidence-based review. Eur Spine J (2005) 1.98
Expression of concern reaffirmed. N Engl J Med (2006) 1.97
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther (2006) 1.96
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 1.95
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
Are journals doing enough to prevent fraudulent publication? CMAJ (2006) 1.89
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ (2006) 1.82
Bidirectional conflicts of interest involving industry and medical journals: who will champion integrity? Mayo Clin Proc (2009) 1.74
Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel (2010) 1.74
Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol (2011) 1.72
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ (2007) 1.71
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis (2007) 1.68
Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken) (2010) 1.68
Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ (2004) 1.66
Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis (2002) 1.64
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther (2005) 1.63
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res (2007) 1.57
Efficacy and safety of COX 2 inhibitors. BMJ (2002) 1.57
Should medical journals carry drug advertising? Yes. BMJ (2007) 1.55
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52
Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther (2007) 1.51
Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf (2012) 1.50
Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest (2001) 1.49
Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med (2006) 1.49
Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health (2011) 1.46
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 1.43
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int (2011) 1.43
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Am J Med Sci (2011) 1.41
Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ (2004) 1.36
Improving ambulatory prescribing safety with a handheld decision support system: a randomized controlled trial. J Am Med Inform Assoc (2005) 1.35
Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol (2006) 1.34
Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol (2009) 1.33
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol (2002) 1.30
Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study. BMC Musculoskelet Disord (2008) 1.30
Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest (2005) 1.30
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A (2010) 1.29
Merck withdraws arthritis drug worldwide. BMJ (2004) 1.28
Is it always unethical to use a placebo in a clinical trial? PLoS Med (2005) 1.28
COX inhibitors and breast cancer. Br J Cancer (2006) 1.27
Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord (2007) 1.27
CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med (2012) 1.26
Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J Gastroenterol (2009) 1.24
Research protocols: waiving confidentiality for the greater good. BMJ (2006) 1.24
Legislation for trial registration and data transparency. Trials (2010) 1.22
Principles for evidence-based drug formulary policy. J Gen Intern Med (2005) 1.22
Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol (2010) 1.22
Arthritis and pain. Neurogenic origin of joint pain. Arthritis Res Ther (2006) 1.21
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 1.21
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut (2003) 1.20
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ (2002) 1.18
Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis (2005) 1.18
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) (2000) 22.00
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum (1998) 12.36
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J (2001) 8.90
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med (1993) 7.29
Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl (1992) 7.04
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med (2000) 5.58
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum (1995) 5.32
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells. Nature (1984) 4.52
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science (1994) 4.50
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Outbreak of HIV infection in a Scottish prison. BMJ (1995) 3.82
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis (2000) 3.81
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Osteoarthritis. Lancet (1997) 3.56
Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med (1993) 3.48
Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res (2001) 3.45
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1994) 3.24
Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ (1992) 3.17
Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology (1985) 3.12
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Intern Med J (2005) 3.08
Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum (1995) 3.05
Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med (2000) 3.01
Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2005) 3.00
Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol (1999) 2.93
Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritis. Arthritis Rheum (1998) 2.89
Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther (2004) 2.83
Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc (2000) 2.80
New radiographic grading scales for osteoarthritis of the hand. Reliability for determining prevalence and progression. Arthritis Rheum (1989) 2.77
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum (2000) 2.71
Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol (1989) 2.67
The influence of ethnicity and race on attitudes toward advance directives, life-prolonging treatments, and euthanasia. J Clin Ethics (1993) 2.66
The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie (1994) 2.64
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63
A proposal for the classification of patients for clinical and experimental studies on reactive arthritis. J Rheumatol (1999) 2.62
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 2.55
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES-I). Am J Epidemiol (1993) 2.54
Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. Arthritis Rheum (1995) 2.51
Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther (1991) 2.44
Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 2.40
Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med (1992) 2.39
Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections. J Proteome Res (2007) 2.38
Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med (1999) 2.38
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2004) 2.38
Family support and conflict: prospective relations to adolescent depression. J Abnorm Child Psychol (1997) 2.38
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med (1996) 2.37
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum (2001) 2.37
Gram-negative bacilli in burns. J Clin Pathol (1969) 2.35
Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol (1993) 2.31
Stressors in ICU: perception of the patient, relatives and health care team. Intensive Care Med (1999) 2.29
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A (1991) 2.27
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Acetaminophen for osteoarthritis. Cochrane Database Syst Rev (2006) 2.21
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Experimental infection of chickens as candidate sentinels for West Nile virus. Emerg Infect Dis (2001) 2.14
Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med (1976) 2.13
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci U S A (1996) 2.10
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Audit of outcome of long-term enteral nutrition by percutaneous endoscopic gastrostomy. Lancet (1993) 2.10
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
[Resource utilization and costs in osteoporosis]. Rev Assoc Med Bras (2002) 2.09
Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. J Rheumatol (1999) 2.07
Family processes in adolescent depression. Clin Child Fam Psychol Rev (2001) 2.07
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Factors associated with functional impairment in symptomatic knee osteoarthritis. Rheumatology (Oxford) (2000) 2.06
Preliminary, dermatologic first step criteria for lupus erythematosus and second step criteria for systemic lupus erythematosus. Int J Dermatol (1993) 2.05
Suppression of leukaemia virus pathogenicity by polyoma virus enhancers. Nature (1985) 2.03
Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest (1966) 2.01
Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) (1985) 2.01
Rationale for tobacco cessation interventions for youth. Prev Med (1998) 2.01
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum (2011) 2.01
Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ (1994) 1.99
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Is diazepam an antidepressant? Br J Psychiatry (1989) 1.96
Adult vitelliform macular detachment occurring in patients with basal laminar drusen. Am J Ophthalmol (1985) 1.96
The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. Arthritis Rheum (1999) 1.96